D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 76 Citations 24,598 201 World Ranking 13822 National Ranking 7170

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

The scientist’s investigation covers issues in Internal medicine, Leukemia, Surgery, Gastroenterology and Cancer research. His research integrates issues of Immunology and Oncology in his study of Internal medicine. His research in Leukemia intersects with topics in Haematopoiesis, Myeloid leukemia and Myelodysplastic syndromes.

His Surgery study incorporates themes from Natural history and Disease. His Gastroenterology study combines topics from a wide range of disciplines, such as Salvage therapy and Cyclophosphamide. Miloslav Beran has researched Cancer research in several fields, including Chronic myelogenous leukemia, Extramedullary hematopoiesis, Philadelphia chromosome and ABL.

His most cited work include:

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy (1097 citations)
  • Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation (814 citations)
  • Report of an international working group to standardize response criteria for myelodysplastic syndromes (636 citations)

What are the main themes of his work throughout his whole career to date?

Miloslav Beran mainly focuses on Internal medicine, Gastroenterology, Leukemia, Surgery and Immunology. Internal medicine is frequently linked to Oncology in his study. Miloslav Beran has included themes like Toxicity, Phases of clinical research, Vincristine, Cyclophosphamide and Alpha interferon in his Gastroenterology study.

His work deals with themes such as Cancer research, Myeloid leukemia and Chronic myelomonocytic leukemia, Myelodysplastic syndromes, which intersect with Leukemia. His Myelodysplastic syndromes course of study focuses on Acute leukemia and Myelofibrosis. The various areas that he examines in his Immunology study include Angiogenesis, Disease and In vivo.

He most often published in these fields:

  • Internal medicine (63.28%)
  • Gastroenterology (42.94%)
  • Leukemia (42.94%)

What were the highlights of his more recent work (between 2004-2015)?

  • Internal medicine (63.28%)
  • Leukemia (42.94%)
  • Gastroenterology (42.94%)

In recent papers he was focusing on the following fields of study:

Miloslav Beran mostly deals with Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Surgery. The Internal medicine study combines topics in areas such as Immunology and Oncology. The concepts of his Leukemia study are interwoven with issues in Cancer research, Chronic myelomonocytic leukemia, Myelodysplastic syndromes, Philadelphia chromosome and Myelofibrosis.

His Cancer research research integrates issues from Chronic myelogenous leukemia, Haematopoiesis and Apoptosis, Programmed cell death. His Gastroenterology research incorporates elements of Phases of clinical research, Adverse effect, Hazard ratio, Nausea and Bone marrow. While the research belongs to areas of Surgery, Miloslav Beran spends his time largely on the problem of Chronic lymphocytic leukemia, intersecting his research to questions surrounding Lumiliximab and Refractory Chronic Lymphocytic Leukemia.

Between 2004 and 2015, his most popular works were:

  • Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation (814 citations)
  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies (559 citations)
  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia (476 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Miloslav Beran mainly investigates Leukemia, Cancer research, Myeloid leukemia, Internal medicine and Chronic myelogenous leukemia. His Cancer research study integrates concerns from other disciplines, such as Cancer and Chronic myelomonocytic leukemia. His Myeloid leukemia research incorporates themes from Hematology and Single-nucleotide polymorphism.

His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Oncology. His Chronic myelogenous leukemia research includes themes of Imatinib, Imatinib mesylate and Philadelphia chromosome. His Philadelphia chromosome research is multidisciplinary, relying on both Myelodysplastic syndromes and Acute leukemia.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg.
Blood (2006)

1581 Citations

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Blood (1997)

1479 Citations

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab.
Cancer Cell (2011)

1215 Citations

Report of an international working group to standardize response criteria for myelodysplastic syndromes

B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto.
Blood (2000)

891 Citations

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes.
Journal of Clinical Oncology (2000)

888 Citations

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero.
Blood (2009)

779 Citations

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes.
Cancer (2004)

724 Citations

Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien.
Blood (2004)

716 Citations

Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl.
Journal of Clinical Oncology (2005)

691 Citations

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy

Hagop M. Kantarjian;Terry L. Smith;Susan O'Brien;Miloslav Beran.
Annals of Internal Medicine (1995)

623 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Miloslav Beran

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 543

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 347

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 266

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 189

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 181

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 148

Stefan Faderl

Stefan Faderl

The University of Texas MD Anderson Cancer Center

Publications: 146

Michael J. Keating

Michael J. Keating

The University of Texas MD Anderson Cancer Center

Publications: 141

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 139

Elihu H. Estey

Elihu H. Estey

University of Washington

Publications: 126

Moshe Talpaz

Moshe Talpaz

University of Michigan–Ann Arbor

Publications: 122

Deborah A. Thomas

Deborah A. Thomas

The University of Texas MD Anderson Cancer Center

Publications: 114

Srdan Verstovsek

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center

Publications: 107

William G. Wierda

William G. Wierda

The University of Texas MD Anderson Cancer Center

Publications: 94

Ross L. Levine

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Publications: 94

Sergio Giralt

Sergio Giralt

Memorial Sloan Kettering Cancer Center

Publications: 94

Trending Scientists

Mathieu d'Aquin

Mathieu d'Aquin

National University of Ireland, Galway

Arie Y. Lewin

Arie Y. Lewin

Duke University

Hassan Zahouani

Hassan Zahouani

École Centrale de Lyon

Xingguo Li

Xingguo Li

Peking University

Milton P. Gordon

Milton P. Gordon

University of Washington

Corrado Romano

Corrado Romano

I.R.C.C.S. Oasi Maria SS

Colin E. Hughes

Colin E. Hughes

University of Zurich

Michael J. Angilletta

Michael J. Angilletta

Arizona State University

T.B. Rodenburg

T.B. Rodenburg

Wageningen University & Research

William R. Pearson

William R. Pearson

University of Virginia

William R. Dickinson

William R. Dickinson

University of Arizona

Vladimir U. Smakhtin

Vladimir U. Smakhtin

International Water Management Institute

Kevin S. Masters

Kevin S. Masters

University of Colorado Denver

Ling Qin

Ling Qin

Chinese University of Hong Kong

Anna Wirz-Justice

Anna Wirz-Justice

University of Basel

Irwin Garfinkel

Irwin Garfinkel

Columbia University

Something went wrong. Please try again later.